Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

Core Viewpoint - The company, Opcon Vision (300595), has recently received a Drug Production License for eye drops from the Anhui Provincial Drug Administration, marking its first acquisition of such a license [1] Group 1: License Acquisition - The Drug Production License is a significant regulatory milestone for the company, allowing it to proceed with further necessary regulatory steps for commercialization [1] - The company must still complete product registration applications, on-site inspections, and compliance checks with Good Manufacturing Practices (GMP) before obtaining the Drug Registration Certificate [1] Group 2: Impact on Business - The acquisition of the Drug Production License is not expected to have a significant short-term impact on the company's operating performance [1]

Core Viewpoint - The company has recently obtained a "Drug Manufacturing License" from the Anhui Provincial Drug Administration, marking its first acquisition of such a license, which is expected to positively influence the company's long-term development [1] Group 1 - The acquisition of the "Drug Manufacturing License" will help optimize the company's product structure [1] - The company still needs to complete regulatory procedures, including product registration application, on-site verification, and compliance checks with GMP, before obtaining the "Drug Registration Certificate" for commercial production and sales [1] - The short-term impact of the "Drug Manufacturing License" on the company's operating performance is expected to be minimal [1]

证券代码：300595 证券简称：欧普康视 公告编号：2026-002 1、企业名称：欧普康视科技股份有限公司 2、统一社会信用代码：91340100723323559X 3、住址（经营场所）：合肥市高新区望江西路 4899 号 欧普康视科技股份有限公司 关于取得《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到安徽省药品监 督管理局颁发的《药品生产许可证》。现将具体情况公告如下： 一、《药品生产许可证》的基本信息 二、对公司的影响及风险提示 4、许可证编号：皖 20250658 5、分类码：Ah 6、法定代表人：陶悦群 7、企业负责人：王殿阔 8、质量负责人：郝展飞 9、生产负责人：陈平 10、质量受权人：郝展飞 11、生产地址和生产范围：合肥市高新区望江西路 4899 号：滴眼剂（注： 未进行药品 GMP 符合性检查，仅限注册申报使用） 12、有效期至：2030 年 12 月 25 日 13、签证机关：安徽省药品监督管理局 本次系公司首次取得《药品生产许可证》，有利于优化公司产品 ...

证券代码：300595 证券简称：欧普康视 公告编号：2026-001 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）的通知，获悉其 将持有公司部分股份补充质押给招商证券股份有限公司。现将具体情况公告如下： 一、股东股份质押的基本情况 注：本公告中所涉数据的尾数差异或不符系四舍五入所致。 2、股份累计被质押的情况 截至本公告披露日，南京欧陶所持质押股份累计情况如下： | | | | 名称 | | 股东 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 量（股） | | 持股数 | | | | | | | （%） 量（股） | | 比例 质押股份数 | 持股 本次质押前 | | | | | | | 量（股） | | 质押股份数 | 本次质押后 | | | | | | （%） ...

Core Viewpoint - The company emphasizes the importance of communication with all shareholders and ensures transparency of information through various channels [1] Group 1: Shareholder Communication - The company has been actively engaging with shareholders through multiple platforms to maintain transparency [1] - The company has conducted online and offline product coupon return activities for shareholders for two consecutive years [1] - The company plans to conduct another shareholder return activity, with specific plans to be announced later [1]

Group 1 - The Anhui Provincial Health Commission and other authorities have released the first batch of "new quality drug and medical device" product catalog to accelerate the promotion and application of innovative medical products, fostering new productive forces in the biopharmaceutical industry [1] - A total of 60 "new quality drug and medical device" products were announced, with 45 products from Hefei, accounting for 75% of the total in the province, highlighting Hefei's strong innovation capabilities and industrial clustering effect [1] - In the biopharmaceutical sector, all three selected biopharmaceuticals in the province are from Hefei, including innovative drugs for tuberculosis/influenza prevention by Zhifei Longcom and anti-tumor drugs by Anke Bio [1] Group 2 - Hefei's Industrial and Information Technology Bureau is actively promoting the innovative development of the biopharmaceutical industry, focusing on building a collaborative industrial ecosystem involving government, industry, academia, research, application, and finance [2] - The city is nurturing local leading enterprises such as Anke Bio, Opcon Vision, and Meiya Optoelectronics while successfully attracting innovative companies like Ruisi Digital Technology through high-level platforms [2] - Collaboration with institutions like the University of Science and Technology of China and Anhui University of Traditional Chinese Medicine has led to the incubation of technology-based SMEs, creating a favorable development pattern for large, medium, and small enterprises [2]

证券代码：300595 证券简称：欧普康视 公告编号：2025-098 欧普康视科技股份有限公司 关于全资子公司对外提供财务资助的进展公告 特此公告。 欧普康视科技股份有限公司 董事会 1 一、财务资助事项概述 欧普康视科技股份有限公司（以下简称"公司"）于 2024 年 3 月 29 日召 开第四届董事会第八次会议，审议通过了《关于全资子公司向参股子公司提供 财务资助的议案》。为满足公司全资子公司欧普康视投资有限公司（以下简称 "欧普投资"）参股公司上海瑞影医疗科技有限公司（以下简称"上海瑞影"） 加快重点研发项目进展的资金需求，保障其业务正常开展，在不影响欧普投资 正常生产经营的情况下，欧普投资以自有资金为上海瑞影提供总额 400 万元的 财务资助，借款期限自款项实际支付至上海瑞影之日起计算，至 2025 年 12 月 31 日止，到期一次性还本付息。借款利率分为附带条件下的无息借款和单利 10%两种，资金划转将以上海瑞影实际的研发进展分批安排。具体内容详见公司 于 2024 年 3 月 30 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于全资子公司对外提供财务资助的公告 ...

Group 1 - The core point of the article is that Opcon Vision (300595) reported a total of 61,914 shareholders as of December 19, 2025 [1]

致：欧普康视科技股份有限公司 天禾律师 股东会法律意见书 安徽天禾律师事务所 关于欧普康视科技股份有限公司 2025 年第三次临时股东会法律意见书 天律意 2025 第 03509 号 券交易所交易系统进行网络投票的时间为 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的时间为 9:15 至 15:00。 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和 国证券法》（下称"《证券法》"）、中国证券监督管理委员会《上市公司股东 会规则》（下称"《股东会规则》"）以及《欧普康视科技股份有限公司章程》 （下称"《公司章程》"）的有关规定，安徽天禾律师事务所接受欧普康视科技 股份有限公司（下称"公司"）委托，指派张大林、冉合庆律师（下称"天禾律 师"）出席公司 2025 年第三次临时股东会（下称"本次股东会"），并对本次 股东会相关事项进行见证，出具法律意见。 本法律意见书是天禾律师根据对本次股东会事实的了解及对我国现行法律、 法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东会的法定必备文件予以公告，并 依法对所出 ...